Bulgari and Dubai Culture announce winner of first Bulgari Contemporary Art Award
23.5.2022 10:38:00 EEST | Business Wire | Press release
In the presence of Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture and Arts Authority (Dubai Culture) and Member of the Dubai Council, Bulgari, the leading Italian brand in the world of jewellery and luxury, and in partnership with Dubai Culture, announced the winner of the first edition of the Bulgari Contemporary Art Award during a ceremony held at the Italy Pavilion at Expo 2020 Dubai. The winner was chosen from a shortlist of three art pieces selected by the award’s jury.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005313/en/
Nima Nabavi, winner of the Bulgari Contemporary Art Award, with the trophy (Photo: AETOSWire)
The ceremony was attended by His Excellency Giuseppe Finocchiaro, Consul-General, Italian Consulate (Dubai); Paolo Glisenti, Italy’s Commissioner General for Expo 2020 Dubai; Jean Christophe Babin, Group CEO of Bulgari; Lucia Boscaini, Brand Curator at Bulgari; Her Excellency Hala Badri, Director General of Dubai Culture; and Dr Saeed Mubarak bin Kharbash, CEO of the Arts and Literature Sector at Dubai Culture.
A panel of three experts — Giuseppe Moscatello, Nujoom Alghanem and Patricia Millns FRSA — visited the exhibition held from 3 to 8 February at the Van de Goudenberg Art Gallery in the Dubai International Financial Centre to celebrate the participating works. Among the 15 artworks, the committee shortlisted three artists: Juma AlHaj (UAE), Dubai-based Kamal Alzubi (Jordan), and Dubai-based artist Nima Nabavi (Iranian-American), who the jury selected for the winning artwork.
Nima Nabavi received a trophy that celebrates the aesthetic and cultural dialogue between Rome and Dubai by combining a silhouette inspired by Bulgari’s iconic doorways and storefronts with architectural ornaments inspired from Dubai’s Al Fahidi and Al Shindagha Historical Neighbourhoods. The trophy was designed by Emirati designer Kamla AlOlama and produced by Asateer, an Emirati studio founded by Mohammed AlSuwaidi specialising in contemporary products that reflect the rich Emirati heritage.
The trophy uses materials with great cultural significance. A frame is fabricated from the rich woods of the UAE’s national tree, Al Ghaf, an emblem of heritage and perseverance. The design also incorporates native mother-of-pearl inlaid motifs and brass.
Nima Nabavi expressed his happiness at winning the award and thanked Bulgari and Dubai Culture for giving him the opportunity to share his artistic vision. He also extended his gratitude to the experts and jury for selecting his work for the award.
The winning artwork was exhibited at the Italy Pavilion in Expo 2020. The artist was also offered the opportunity to experience Rome through the eyes of Bulgari as part of a week-long journey through the brand’s universe. He will experience the beauty of Bulgari’s colourful gems and visit the DomvsAvrea museum space in the Maison’s flagship store in Rome, as well as attend workshops with Bulgari designers and exclusive tours of historical sites and cultural locations particularly linked with Bulgari’s patronage, initiatives and inspiration. In addition, the winning piece will be exhibited at venues associated with Dubai Culture and Bulgari, according to a pre-defined schedule.
Launched in July 2021, the Bulgari Contemporary Art Award opened the door for UAE national and resident artists to submit artworks under the theme ‘Beauty Connects People’ that had them creatively express how beauty connects people and how cities like Dubai and Rome are linked by their inspirational beauty and innovation.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005313/en/
Contact information
Antoine Boghos, +971503310001
Email address: antoine@cbpr.me
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom